Human induced pluripotent stem cells (iPSCs) have the unique capacity to be indefinitely expanded and differentiated in culture into any type of cell in the body. The groundbreaking discovery that fully differentiated human cells can be induced to a pluripotent state through the expression of certain genes was recognized with the award of the 2012 Nobel Prize in Science and Medicine. iPSCs represent an ideal cell source for creating cell therapy product candidates that are well-defined, uniform in composition and can be delivered off-the-shelf for the treatment of large numbers of patients.
We are applying our expertise in induced pluripotent stem cell biology to genetically engineer, single-cell isolate and select iPSCs for clonal expansion as master iPSC lines. We direct the fate of master iPSC lines to create cells of the immune system, including NK cells, T cells and CD34+ cells, and are advancing a pipeline of off-the-shelf cellular immunotherapies derived from master iPSC lines.
As a key component of the innate immune system, Natural Killer, or NK, cells are the body’s first line of defense against disease. NK cells can directly seek out and kill abnormal cells, such as cancer or virally-infected cells, while leaving normal cells unharmed. Unlike T cells that require tumor-antigen recognition for effector function, NK cells can selectively identify stress ligands commonly expressed on tumor cells and secrete cytotoxic granules, triggering rapid cell death. Additionally, NK cells can also release pro-inflammatory cytokines after engaging tumor cells, stimulating a durable anti-tumor response by other immune cells. Through these direct and indirect anti-tumor mechanisms, NK cells can bridge innate and adaptive immunity and drive a potent, multi-dimensional, and long-lived immunological response for the treatment of cancer.
We are developing a pipeline of iPSC-derived NK cell product candidates for the treatment of cancer, including through our collaborations with the University of Minnesota and Oslo University Hospital. We are executing on a multi-pronged clinical development strategy including investigation of our NK cell product candidates as monotherapy and in combination with other anti-tumor agents such as monoclonal antibodies.
T cells, or T-lymphocytes, play a central role in adaptive immunity. T cells are distinguished from other immune cells by their expression of T cell receptors (TCRs) on their cell surface that can recognize a specific antigen on a cancer cell. Upon antigen recognition, T cells bind to major histocompatibility complex (MHC) molecules, become activated, release cytokines and induce target cell death. T-cell cancer immunotherapy today is a personalized treatment, requiring the sourcing, isolation, engineering and expansion of T cells from an individual patient for subsequent delivery back to that same patient.
We believe that engineering functionality into master iPSC lines is a potential breakthrough approach to T-cell cancer immunotherapy, and that iPSC-derived T-cell product candidates can be efficiently and consistently manufactured, and safely and reliably delivered, at the scale necessary to support broad patient access and wide-spread commercialization. We are developing a pipeline of engineered iPSC-derived T-cell product candidates for the treatment of cancer, including through our collaboration with Memorial Sloan Kettering Cancer Center.